Enzyme kinetics of cytochrome P450-mediated reactions

被引:90
|
作者
Shou, M
Lin, Y
Lu, P
Tang, C
Mei, Q
Cui, D
Tang, W
Ngui, JS
Lin, CC
Singh, R
Wong, BK
Yergey, JA
Lin, JH
Pearson, PG
Baillie, TA
Rodrigues, AD
Rushmore, TH
机构
[1] Merck Res Labs, Dept Drug Metab, W Point, PA 19486 USA
[2] Merck Res Labs, Dept Drug Metab, Rahway, NJ 07065 USA
关键词
D O I
10.2174/1389200013338784
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The most common drug-drug interactions may be understood in terms of alterations of metabolism, associated primarily with changes in the activity of cytochrome P450 (CYP) enzymes. Kinetic parameters such as K-m, V-max, K-i and K-a, which describe metabolism-based drug interactions, are usually determined by appropriate kinetic models and may be used to predict the pharmacokinetic consequences of exposure to one or multiple drugs. According to classic Michaelis-Menten (M-M) kinetics, one binding site models can be employed to simply interpret inhibition (pure competitive, non-competitive and uncompetitive) or activation of the enzyme. However, some cytochromes P450, in particular CYP3A4, exhibit unusual kinetic characteristics. In this instance, the changes in apparent kinetic constants in the presence of inhibitor or activator or second substrate do not obey the rules of M-M kinetics, and the resulting kinetics are not straightforward and hamper mechanistic interpretation of the interaction in question. These unusual kinetics include substrate activation (autoactivation), substrate inhibition, partial inhibition, activation, differential kinetics and others. To address this problem, several kinetic models can be proposed, based upon the assumption that multiple substrate binding sites exist at the active site of a particular P450, and the resulting kinetic constants are, therefore, solved to adequately describe the observed interaction between multiple drugs. The following is an overview of some cytochrome P450-mediated classic and atypical enzyme kinetics, and the associated kinetic models. Applications of these kinetic models can provide some new insights into the mechanism of P450-mediated drug-drug interactions.
引用
收藏
页码:17 / 36
页数:20
相关论文
共 50 条
  • [1] Kinetics and regulation of cytochrome P450-mediated etoposide metabolism
    Zhuo, XL
    Zheng, NY
    Felix, CA
    Blair, IA
    DRUG METABOLISM AND DISPOSITION, 2004, 32 (09) : 993 - 1000
  • [2] An assessment of the reaction energetics for cytochrome P450-mediated reactions
    Higgins, L
    Korzekwa, KR
    Rao, S
    Shou, MG
    Jones, JP
    ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2001, 385 (01) : 220 - 230
  • [3] Cytochrome P450-mediated drug interactions
    Flockhart, DA
    Oesterheld, JR
    CHILD AND ADOLESCENT PSYCHIATRIC CLINICS OF NORTH AMERICA, 2000, 9 (01) : 43 - +
  • [4] Models for cytochrome P450-mediated metabolism
    Korzekwa, KR
    Ewing, TJ
    Kocher, JP
    Carlson, TJ
    Pharmaceutical Profiling in Drug Discovery for Lead Selection, 2004, 1 : 69 - 80
  • [5] Predicting the regioselectivity and stereoselectivity of cytochrome P450-mediated reactions - Structural models for bioactivation reactions
    Jones, JP
    Shou, M
    Korzekwa, KR
    BIOLOGICAL REACTIVE INTERMEDIATES V: BASIC MECHANISTIC RESEARCH IN TOXICOLOGY AND HUMAN RISK ASSESSMENT, 1996, 387 : 355 - 360
  • [6] Plant cytochrome P450-mediated herbicide metabolism
    Siminszky B.
    Phytochemistry Reviews, 2006, 5 (2-3) : 445 - 458
  • [7] Cytochrome P450-mediated drug metabolism in the brain
    Miksys, Sharon
    Tyndale, Rachel F.
    JOURNAL OF PSYCHIATRY & NEUROSCIENCE, 2013, 38 (03): : 152 - 163
  • [8] Cytochrome P450-mediated cardiovascular drug interactions
    Scheen, Andre J.
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2011, 7 (09) : 1065 - 1082
  • [9] In Vitro Cytochrome P450-Mediated Metabolism of Exemestane
    Kamdem, Landry K.
    Flockhart, David A.
    Desta, Zeruesenay
    DRUG METABOLISM AND DISPOSITION, 2011, 39 (01) : 98 - 105
  • [10] Cytochrome P450-mediated metabolism of capsaicin: Bioactivation or detoxification?
    Reilly, CA
    Smeal, SJ
    Yost, GS
    DRUG METABOLISM REVIEWS, 2002, 34 : 59 - 59